Amyloid-Journal of Protein Folding Disorders

Papers
(The median citation count of Amyloid-Journal of Protein Folding Disorders is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
A second case of liraglutide-type localised amyloidosis219
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies201
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration95
Changes in the amyloid editorial board members and in editor positions81
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey62
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis40
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study34
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases28
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange26
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging24
Survey of amyloidosis cases among different free-living wild and zoo animals24
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains21
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy19
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis18
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition17
Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis16
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy16
Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis15
Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies14
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay14
Alterations in multi-layer strain in AL amyloidosis13
A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)13
Identification of epidermal growth factor-containing fibulin-like extracellular matrix protein 1-derived amyloid deposition in a rhesus macaque13
Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis12
Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice12
Management of AL amyloidosis in 2021+12
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis12
Left atrioventricular coupling index assessed with three-dimensional echocardiography: a prognostic marker of short-term outcomes in light-chain cardiac amyloidosis12
Selective recognition of human small transthyretin aggregates by a novel monoclonal antibody11
Utilization and tolerance of beta-blockers among patients with AL amyloidosis10
Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study10
Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China10
Brain MRI in patients with V30M hereditary transthyretin amyloidosis9
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures9
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage9
Refining prognostication in systemic AL amyloidosis: limited value of dFLC9
Monitoring of cardiac transthyretin amyloid load by [99mTc]DPD scintigraphy: is it the end of the semi-quantitative evaluation?8
Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis8
A rare occurrence and near miss! Should a TTR gene test be routinely performed for suspected ATTR-cardiomyopathy?8
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee8
Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation8
Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours7
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis7
Correction7
Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant7
Abnormal electrochemical skin conductance values in patients with AA amyloidosis7
Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation7
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines7
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution7
Incidence and predictors of sudden death in patients with cardiac amyloidosis6
Subtyping of cardiac amyloidosis by mass spectrometry-based proteomics of endomyocardial biopsies6
Epidemiology of hereditary transthyretin amyloidosis in the northernmost region of Sweden: a retrospective cohort study6
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study6
Complete remission after patisiran treatment in a patient with nephrotic syndrome secondary to hereditary transthyretin amyloidosis (ATTR)6
Neuropathy progression in hereditary transthyretin amyloidosis (ATTRv) patients after liver transplantation5
Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis5
The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up5
Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis5
A family with extremely early onset ATTRv amyloidosis and an F44S mutation in China5
Detection of ATTR aggregates in the plasma of polyneuropathic patients with ATTR-V30M amyloidosis5
Reduction in 99m Tc-DPD myocardial uptake with therapy of ATTR cardiomyopathy5
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant5
Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis5
Altered connectivity of central autonomic network: effects of dysautonomia in hereditary transthyretin amyloidosis with polyneuropathy5
Heterogeneity in families with ATTRV30M amyloidosis: a historical and longitudinal Portuguese case study impact for genetic counselling5
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis5
High rate of false negative 99m Tc-pyrophosphate scintigraphy scans in patients with Leu58His transthyretin amyloid cardiomyopathy5
Progressive vitreous deposits during treatment with inotersen for hereditary ATTR amyloidosis5
Computed tomography-derived myocardial radiomics for detection of transthyretin amyloidosis in patients with severe aortic stenosis4
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee4
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays4
High frequency of occult transthyretin and apolipoprotein AI–type amyloid in aortic valves removed by valve replacement for aortic stenosis4
A novel substitution of proline (P32L) destabilises β2-microglobulin inducing hereditary systemic amyloidosis4
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study4
Post-translational modification of amyloid a protein in patients with AA amyloidosis4
The way to a man’s heart: prostate samples for the early detection of transthyretin cardiomyopathy4
Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy4
Binding of serum-derived amyloid-associated proteins to amyloid fibrils3
No body fits in the test tube – the case of transthyretin3
ATTR- and AFib amyloid - two different types of amyloid in the annular ligament of trigger finger3
Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?3
Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program3
Internalisation of immunoglobulin light chains by cardiomyocytes in AL amyloidosis: what can biopsies tell us?3
Myelopathy in hereditary ATTR Val30Met amyloidosis patients3
AA amyloidosis in vertebrates: epidemiology, pathology and molecular aspects3
Usefulness of the Columbia score for predicting outcomes in patients with transthyretin amyloid cardiomyopathy. Analysis of the Galician registry of cardiac amyloidosis3
Transthyretin monomers: a new plasma biomarker for pre-symptomatic transthyretin-related amyloidosis3
Mass spectrometry-based proteomic analysis of proteins adsorbed by hexadecyl-immobilized cellulose bead column for the treatment of dialysis-related amyloidosis3
Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis3
Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA)3
Longitudinal PET/CT imaging with iodine ( 124 I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis3
Identification of calcitonin receptor-stimulating peptide 1-derived amyloid in a feline C-cell carcinoma3
Iatrogenic cerebral amyloid angiopathy rather than sporadic CAA in younger adults with lobar intracerebral haemorrhage2
The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis2
Genetic counselling for at-risk family members with hereditary transthyretin amyloidosis: data from a single-centre study2
XIX International Symposium on Amyloidosis Abstracts2
CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis2
Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis2
Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and2
A report from the European Proteomics Amyloid Network (EPAN)2
Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosis2
In memoriam: Lawreen Connors, Ph.D.2
Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis2
Hereditary gelsolin amyloidosis: a rare cause of cranial, peripheral and autonomic neuropathies linked to D187N and Y447H substitutions2
Hereditary transthyretin amyloidosis in middle-aged and elderly patients with idiopathic polyneuropathy: a nationwide prospective study2
Collagen inhibits phagocytosis of amyloid in vitro and in vivo and may act as a ‘don’t eat me’ signal2
Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis2
0.072393178939819